X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DR. REDDYS LAB - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DR. REDDYS LAB SUN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 38.0 31.8 119.6% View Chart
P/BV x 4.2 3.4 123.7% View Chart
Dividend Yield % 0.5 0.8 70.5%  

Financials

 SUN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
DR. REDDYS LAB
Mar-18
SUN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs8422,788 30.2%   
Low Rs5721,902 30.1%   
Sales per share (Unadj.) Rs131.6860.8 15.3%  
Earnings per share (Unadj.) Rs32.757.1 57.3%  
Cash flow per share (Unadj.) Rs38.0122.0 31.1%  
Dividends per share (Unadj.) Rs3.5020.00 17.5%  
Dividend yield (eoy) %0.50.9 58.0%  
Book value per share (Unadj.) Rs152.7757.7 20.2%  
Shares outstanding (eoy) m2,399.26165.91 1,446.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.42.7 197.3%   
Avg P/E ratio x21.641.1 52.6%  
P/CF ratio (eoy) x18.619.2 96.9%  
Price / Book Value ratio x4.63.1 149.7%  
Dividend payout %10.735.0 30.5%   
Avg Mkt Cap Rs m1,696,877389,034 436.2%   
No. of employees `00017.523.5 74.5%   
Total wages/salary Rs m49,02332,149 152.5%   
Avg. sales/employee Rs Th18,028.36,070.8 297.0%   
Avg. wages/employee Rs Th2,798.81,366.6 204.8%   
Avg. net profit/employee Rs Th4,479.5402.5 1,113.0%   
INCOME DATA
Net Sales Rs m315,784142,810 221.1%  
Other income Rs m6,2321,552 401.5%   
Total revenues Rs m322,016144,362 223.1%   
Gross profit Rs m100,89323,512 429.1%  
Depreciation Rs m12,64810,772 117.4%   
Interest Rs m3,998788 507.4%   
Profit before tax Rs m90,47913,504 670.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m99344 28.9%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1164,380 276.6%   
Profit after tax Rs m78,4629,468 828.7%  
Gross profit margin %31.916.5 194.1%  
Effective tax rate %13.432.4 41.3%   
Net profit margin %24.86.6 374.8%  
BALANCE SHEET DATA
Current assets Rs m329,537104,984 313.9%   
Current liabilities Rs m178,87068,938 259.5%   
Net working cap to sales %47.725.2 189.0%  
Current ratio x1.81.5 121.0%  
Inventory Days Days7974 106.2%  
Debtors Days Days83104 80.4%  
Net fixed assets Rs m204,766104,385 196.2%   
Share capital Rs m2,399830 289.1%   
"Free" reserves Rs m363,997124,886 291.5%   
Net worth Rs m366,397125,716 291.4%   
Long term debt Rs m14,36125,089 57.2%   
Total assets Rs m614,102225,443 272.4%  
Interest coverage x23.618.1 130.3%   
Debt to equity ratio x00.2 19.6%  
Sales to assets ratio x0.50.6 81.2%   
Return on assets %13.44.5 295.2%  
Return on equity %21.47.5 284.3%  
Return on capital %24.89.7 255.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,11872,623 60.7%   
Fx outflow Rs m24,48418,916 129.4%   
Net fx Rs m19,63453,707 36.6%   
CASH FLOW
From Operations Rs m70,82218,030 392.8%  
From Investments Rs m-42,216-14,883 283.7%  
From Financial Activity Rs m-22,854-4,440 514.7%  
Net Cashflow Rs m6,107-1,236 -494.1%  

Share Holding

Indian Promoters % 63.7 25.5 249.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 5.4 95.0%  
FIIs % 23.0 35.3 65.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 8.3 15.3 54.2%  
Shareholders   133,026 75,885 175.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS